Toggle navigation
Browse
Home
Researchers
Research Departments
Publications
About/Support
Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).
Meeting Abstract
Industry Collaboration
Overview
Research
Additional Document Info
View All
Overview
cited authors
Fisher, Terrence Lee; Evans, Elizabeth E.; Mallow, Crystal L.; Foster, Amber; Boise, Megan; Smith, Ernest; Leonard, John E.; Chaney, Marya F.; Beck, Joseph Thaddeus; Hager, Steven Jeffrey; Mekhail, Tarek; Seetharamu, Nagashree; Baumgart, Megan; Saba, Nabil F.; Steuer, Conor Ernst; Adkins, Douglas; Burtness, Barbara; Zauderer, Maurice
Publication Date
June 1, 2022
webpage
Web of Science
published in
JOURNAL OF CLINICAL ONCOLOGY
Journal
Research
category
ONCOLOGY
Web of Science Category
Additional Document Info
start page
E18033
end page
E18033
volume
40
issue
16